Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson to distribute alendronate tablets
Under the terms of a supply agreement, Merck will manufacture and supply the alendronate sodium tablets to Watson, which will market, sell and distribute the product in the
Under the terms of a supply agreement, Merck will manufacture and supply the alendronate sodium tablets to Watson, which will market, sell and distribute the product in the
Dan McMahon, director of marketing, CytoCore, said: “We are in the final stages of completing the North American distribution organization and expect to be able to launch the
The Nucleonics’s HBV clinical candidate (NUC B1000) is an expressed interfering RNA (eiRNA) based product, consisting of a plasmid DNA construct that encodes four short interfering RNA (siRNA)
The total deal, valued at up to $9.65 million, provides for the formation of a 50/50 joint venture entity that will own, develop and secure a commercialization partner
Under the terms of the agreement, Agilent will make an undisclosed settlement payment to Invitrogen. In addition, Agilent will discontinue sales of its RNase H minus RT products
The open label trial was designed to assess the safety and pharmacokinetic profile of Thallion’s new continuous intravenous formulation of CAP-232, as well as provide efficacy data in
Under the regulation, a paediatric investigation plan, or PIP, must accompany all new product approval applications in the EU from July 26, 2008. The same applies to applications
According to the Department of Health, the new guidance has been designed to provide advice on how primary care trusts, pharmaceutical companies and clinicians can work side by
Medicines which have not been approved by the SFDA and foreign-made drugs and devices which have not received approval in their country of origin, or which are approved
The list covers 11 active ingredients in 30 presentations, most notably Japan’s top-selling prescription drug, Takeda’s Blopress (candesartan). The antidepressants to be repriced include Paxil (paroxetine, GlaxoSmithKline), Depromel/Luvox